Gastric Triacylglycerol Lipase (LIPF)

Specification

• Cat#: THP-0261
• Product Name: Gastric Triacylglycerol Lipase (LIPF)
• Description: A DNA sequence encoding the human LIPF (Met1-Lys398) was expressed with a C-terminal polyhistidine tag.
• Species: Human
• Molecular Weight: The secreted recombinant human LIPF consists of 389 amino acids and predicts a molecular mass of 44.6 KDa. The apparent molecular mass of the protein is approximately 45 KDa in SDS-PAGE under reducing conditions.
• Source: Baculovirus-Insect cells
• Introduction: The protein Gastric triacylglycerol lipase (LIPF) is the target for the small-molecule antagonist Orlistat (brand names Alli and Xenical), which is used to treat obesity by preventing the absorption of fats from the diet. LIPF is an enzyme that hydrolyzes triglycerides into absorbable free fatty acids in the intestine, here shown in the glandular cells in stomach by immunohistochemical staining with the antibody.
• Purity: > 95 % as determined by SDS-PAGE
• Formulation: Lyophilized from sterile PBS, pH 7.4.

Pharmaceutical Information

• Applications: This protein is used to treat obesity by preventing the absorption of fats from the diet.
• Examples of Clinical Use: Treating obesity by preventing the absorption of fats from the diet.
• Affected organisms: Humans